Comparability Assessments of Process Changes Made during Development of Anti-Idiotype Vaccine


Racotumomab monoclonal antibody is a murine anti-idiotypic antibody. This monoclonal antibody mimics N-glycolyl-GM3 gangliosides has been tested in several clinical trials Phase I/II for breast, melanoma and non-small cell lung cancer patients as an anti-idiotypic cancer vaccine. The early production process was performed in vivo from mice ascites fluid. This process was transferred to bioreactor-based method at pilot scale followed to the scale-up of the fermentation. In this work we present a comprehensive molecular characterization of racotumomab MAb produced by the two different production scales in order to determine the impact of the manufacturing process in vaccine performance. We observed differences in glycosylation pattern and charge heterogeneity between racotumomab produced in both scales. Interestingly, these modifications had no significant impact on biological activity elicited in chickens. So, changes in primary structure like glycosylation, charge heterogeneity and oxidation did not affect biological activity of the vaccine.

Share and Cite:

K. Luz-Hernández, Y. Rabasa, R. Montesinos, D. Fuentes, J. Tomás, O. Morales, Y. Aguilar, B. Pacheco, A. Castillo and A. Vazquez, "Comparability Assessments of Process Changes Made during Development of Anti-Idiotype Vaccine," World Journal of Vaccines, Vol. 4 No. 1, 2014, pp. 24-32. doi: 10.4236/wjv.2014.41005.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] A. M. Vázquez, A. Perez, A. M. Hernandez, A. Macias, M. Alfonso, G. Bombino and R. Perez, “Syngeneic Anti-Idiotypic Monoclonal Antibodies to an Anti-Neugc-Containing Ganglioside Monoclonal Antibody,” Hybridoma, Vol. 17, No. 6, 1998, pp. 527-534.
[2] A. M. Vázquez, M.Alfonso, B. Lanne, K. A. Karlsson, A. Carr, O. Barroso, L. E. Fernández, E. Rengifo, M. E. Lanio, C. Alvarez, J. Zeuthen and R. Pérez, “Generation of a Murine Monoclonal Antibody Specific for N-Glycolylneuraminic Acid-Containing Gangliosides That Also Recognizes Sulfated Glycolipids,” Hybridoma, Vol. 14, No. 6, 1995, pp. 551-556.
[3] E. Moreno, B. Lanne, A. M. Vazquez, I. Kawashima, T. Tai, L. E. Fernandez, K. A. Karlsson, J. Angstrom and R. Perez, “Delineation of the Epitope Recognized by an Antibody Specific for Nglycolylneuraminic Acid-Containing Gangliosides,” Glycobiology, Vol. 8, No. 7, 1998, pp. 695-705.
[4] M. Alfonso, A. Diaz, A. M. Hernandez, A. Perez, E. Rodriguez, R. Bitton, R. Perez and A. M. Vázquez, “An Anti-Idiotype Vaccine Elicits a Specific Response to N-Glycolyl Sialic Acid Residues of Glycoconjugates in Melanoma Patients,” The Journal of Immunology, Vol. 168, 2002, pp. 2523-2529.
[5] E. Neninger, R. M. Diaz, A. de la Torre, G. Suarez, M. R. Gabri, D. S. Alonso, B. Wilkinson, A. M. Alfonso, T. Crombet, R. Perez and A. M. Vázquez, “Active Immunotherapy with Racotumomab Anti-Idiotype Vaccine in Patients with Small Cell Lung Cancer: Report of a Phase I Trial,” Cancer Biology & Therapy, Vol. 6, 2007, pp. 145- 150.
[6] G. Marquina, H. Waki, L. E. Fernández, K. Kon, A. Carr, O. Valiente, R. Pérez and S. Ando, “Gangliosides Expressed in Human Breast Cancer,” Cancer Research, Vol. 56, 1996, pp. 5165-5171.
[7] A. M. Vazquez, M. R. Gabri, A. M. Hernandez, D. F. Alonso, I. Beausoleil, D. E. Gómez and R. Perez, “Antitumor Properties of an Anti-Idiotypic Monoclonal Antibody in Relation to Nglycolylcontaining Gangliosides,” Oncology Reports, Vol. 7, 2000, pp. 751-756.
[8] Y. Diaz, A. Gonzalez, A. López, R. Pérez, A. M. Vázquez and E. Montero, “Anti-Ganglioside Anti-Idiotypic Monoclonal Antibody-Based Cancer Vaccine Induces Apoptosis and Antiangiogenic Effect in a Metastatic Lung Carcinoma,” Cancer Immunology, Immunotherapy, Vol. 58, No. 7, 2009, pp. 1117-1128.
[9] M. Guthmann, M. Castro, G. Cinat, C. Venier, L. Koliren, R. Bitton, A. M. Vazquez and L. Fainboim, “Cellular and Humoral Immune Response to N-Glycolyl-GM3 Elicited by Prolongued Immunotheraphy with an Anti-Idiotypic Vaccine in Hgh-Risk and Metastatic Breast Cancer Patients,” Journal of Immunotherapy, Vol. 29, No. 2, 2006, pp. 215-223.
[10] A. Diaz, M. Alfonso, R. Alonso, G. Suarez, M. Troche, M. Catala, R. M. Diaz, R. Pérez and A. M. Vázquez, “Immune Responses in Breast Cancer Patients Immunized with an Antiidiotype Antibody Mimicking NeuGc- Containing Gangliosides,” Clinical Immunology, Vol. 107, No. 2, 2003, pp. 80-89.
[11] V. Segatori, A. M. Vazquez, D. E. Gomez, M. R. Gabri, and D. F. Alonso, “Preclinical Evaluation of Racotumomab, an Anti-Idiotype Monoclonal Antibody to N-Glyco- lyl-Containing Gangliosides, with or Without Chemotherapy in a Mouse Model of Non-Small Cell Lung Cancer,” Frontiers in Oncology, Vol. 2, 2012, p. 160.
[12] A. M. Vázquez, A. M. Hernández, A. Macías, E. Montero, D. E. Gómez, D. F. Alonso, M. R. Gabri and R. E. Gómez, “Racotumomab: An Anti-Idiotype Vaccine Related to N-Glycolyl-Containing Gangliosides—Preclinical and Clinical Data,” Frontiers in Oncology, Vol. 2, 2012, p. 150.
[13] Y. J. Machado, Y. Rabasa, R. Montesinos, J. Cremata, V. Besada, D. Fuentes, A. Castillo, K. R. de la Luz, A. M. Vázquez and M. Himly, “Physicochemical and Biological Characterization of 1E10 Anti-Idiotype Vaccine,” BMC Biotechnology, Vol. 11, 2011, p. 112.
[14] H. Liu, G. Gaza-Bulseco, T. Xiang and C. Chumsae, “Structural Effect of Deglycosylation and Methionine Oxidation on a Recombinant Monoclonal Antibody,” Molecular Immunology, Vol. 45, No. 3, 2008, pp. 701-708.
[15] A. J. Chirino and A. Mire-Sluis, “Characterizing Biological Products and Assessing Comparability Following Manufacturing Changes,” Nature Biotechnology, Vol. 22, No. 11, 2004, pp. 1383-1391.
[16] C. H. Chung, B. Mirakhur, E. Chan, Q. T. Le, J. Berlin, M. Morse, B. A. Murphy, S. M. Satinover, J. Hosen, D. Mauro, et al: Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-Alpha-1,3-Galactose,” The New England Journal of Medicine, Vol. 358, No. 11, 2008, pp. 1109-1117.
[17] M. Paborji, N. L. Pochopin, W. P. Coppola, J. B. Bogardus, “Chemical and Physical Stability of Chimeric L6, a Mouse-Human Monoclonal Antibody,” Pharmaceutical Research, Vol. 11, No. 5, 1994, pp. 764-771.
[18] J. Vlasak, M. C. Bussat, S. Wang, E. Wagner-Rousset, M. Schaefer, C. Klinguer-Hamour, M. Kirchmeier, N. Corvaia, R. Ionescu and A. Beck, “Identification and Characterization of Asparagine Deamidation in the Light Chain CDR1 of a Humanized IgG1 Antibody,” Analytical Biochemistry, Vol. 392, No. 2, 2009, pp. 145-154.
[19] A. Beck, M. C. Bussat, N. Zorn, V. Robillard, C. Klinguer-Hamour, S. Chenu, L. Goetsch, N. Corvaia, A. Van Dorsselaer and J. F. Haeuw, “Characterization by Liquid Chromatography Combined with Mass Spectrometry of Monoclonal Anti-IGF-1 Receptor Antibodies Produced in CHO and NS0 Cells,” Journal of Chromatography B, Vol. 819, No. 2, 2005, pp. 203-218.
[20] A. Beck, M. C. Bussat, N. Zorn, V. Robillard, C. Klinguer-Hamour, S. Chenu, L. Goetsch, N. Corvaia, A. Van Dorsselaer and J. F. Haeuw, “Characterization by Liquid Chromatography Combined with Mass Spectrometry of Monoclonal Anti-IGF-1 Receptor Antibodies Produced in CHO and NS0 cells,” Journal of Chromatography B, Vol. 819, No. 2, 2005, pp. 203-218.
[21] D. A. Lewis, A. W. Guzzetta, W. S. Hancock and M. Costello, “Characterization of Humanized Anti-TAC, an Antibody Directed against the Interleukin 2 Receptor, Using Electrospray Ionization Mass Spectrometry by Direct Infusion, LC/MS, and MS/MS,” Analytical Chemistry, Vol. 66, No. 5, 1994, pp. 585-595.
[22] S. Wang, R. Ionescu, N. Peekhaus, J. Y. Leung, S. Ha and J. Vlasak, “Separation of Post-Translational Modifications in Monoclonal Antibodies by Exploiting Subtle Conformational Changes under Mildly Acidic Conditions,” Journal of Chromatography A, Vol. 1217, No. 42, 2005, pp. 6496-6502.
[23] G. R. Guile, S. Y. Wong and R. A. Dwek, “Analytical and Preparative Separation of Anionic Oligosaccharides by Weak Anion-Exchange High-Performance Liquid Chromatography on an Inert Polymer Column,” Analytical Biochemistry, Vol. 222, No. 1, 1994, pp. 231-235.
[24] M. C, Manning, K. Patel and R. T. Borchardt, “Stability of Protein Pharmaceuticals,” Pharmaceutical Research, Vol. 6, No. 11, 1989, pp. 903-918.
[25] R. J. Harris, “Processing of C-Terminal Lysine and Arginine Residues of Proteins Isolated from Mammalian Cell Culture,” Journal of Chromatography A, Vol. 705, No. 1, 1995, pp. 129-134.
[26] J. M. Reichert, A. Beck and H. Iyer, “European Medicines Agency Workshop on Biosimilar Monoclonal Antibodies,” MAbs, Vol. 1, No. 5, 2009, pp. 394-416.
[27] G. Cabrera, J. A. Cremata, R. Valdes, R. Garcia, Y. Gonzalez, R. Montesino, H. Gomez and M. Gonzalez, “Influence of Culture Conditions on the N-Glycosylation of a Monoclonal Antibody Specific for Recombinant Hepatitis B Surface Antigen,” Biotechnology and Applied Biochemistry, Vol. 41, No. 1, 2005, pp. 67-76.
[28] Glycosylation Patterns during Fermentation, “Practical High-Throughput Monitoring during Process Development and Manufacturing,” Genetic Engineering and Biotechnology News, Vol. 26, 2006, N.8.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.